<DOC>
	<DOCNO>NCT01503918</DOCNO>
	<brief_summary>The purpose study determine whether reactivation latent cytomegalovirus infection critically ill patient look intensive care unit successfully safely prevent use antiviral agent . Comparison make standard care , treatment one two different antiviral regimen : valaciclovir/aciclovir , favourable side effect profile require high dosage effective , valganciclovir/ganciclovir , side effect , demonstrate effective low dosage . The primary hypothesis cytomegalovirus reactivation effectively suppress antiviral prophylaxis .</brief_summary>
	<brief_title>Cytomegalovirus Control Critical Care</brief_title>
	<detailed_description>Background : * Cytomegalovirus ( CMV ) common virus infects around half UK population . Infection usually mild , infection virus never completely eradicate , may reactivate ill health . Reactivation commonly see compromise immune system , people advance HIV infection , whilst immunosuppression follow organ transplantation . CMV reactivation patient life threaten . There evidence support use antiviral medication group immunosuppressed patient prevent CMV reactivation , use part standard therapy . There increase evidence demonstrate third critically ill patient reactivate CMV , patient much double mortality . Aims : * This study proof concept study design ass whether antiviral prophylaxis effectively safely suppress CMV reactivation CMV seropositive high risk critically ill patient . Antiviral prophylaxis currently standard practice critical care unit , previous trial prophylaxis undertaken setting . All commonly use antiviral agent side effect , important demonstrate efficacy safety critical care set undertake large multicentre trial power identify mortality morbidity difference prophylaxis . Intravenous ganciclovir , oral prodrug valganciclovir effectively use prophylaxis low dos immunosuppressed patient . Intravenous aciclovir oral prodrug valaciclovir high dosage also demonstrate effective prophylaxis immunosuppressed patient . This study set determine whether use critically ill patient effective safe . Plan Investigation : * This prospective , randomised , open-label single centre study . Patients admit Queen Elizabeth Hospital Birmingham critical care unit , identify study criterion high risk CMV reactivation assess inclusion study . Blood analyse CMV antibody establish eligibility . Recruited patient randomise receive high dose aciclovir/valaciclovir , low dose ganciclovir/valganciclovir duration critical care stay , maximum 28 day , enter control group receive standard care . CMV viral load polymerase chain reaction ( PCR ) measure blood , throat swab , urine , sputum via non-directed bronchiolar lavage ( NDBL ) twice weekly . Potential Impact : * Latent CMV infection common , affect around half adult UK . Evidence demonstrate third patient reactivate lead CMV viraemia critically ill. Epidemiological data multiple independent group identify double mortality group , although causal link CMV reactivation mortality without trial antiviral drug assume . From figure , estimate 16.5 % critically ill patient ( current mortality rate around 40 % ) may benefit antiviral prophylaxis . Almost patient receive prophylaxis screen reactivation worldwide group . Demonstration mortality morbidity improvement could potentially change worldwide intensive care practice .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Total hospital stay le 7 day CMV seropositive Critical care stay &gt; 24 hour Mechanically ventilate , anticipated continue &gt; 48 hour Known Pregnancy breast feeding Expected survive le 48 hour Confirmed immunosuppression Known suspect Human Immunodeficiency Virus infection Known suspect underlying immunodeficiency ( organ transplantation include stem cell transplantation immunosuppression , congenital immunodeficiency , receipt immunosuppressive medication e.g . azathioprine , methotrexate , tacrolimus , cyclosporine , sirolimus , cyclophosphamide within 30 day ) Corticosteroids : Prednisolone chronic administration may use dose 10mg/day average precede 30 day , stress dose hydrocortisone ( 400mg/day ) may use , topical steroid may use , short duration high dose steroid exacerbation chronic obstructive pulmonary disease ( COPD ) 1mg/kg prednisolone equivalent permit 14 day Receipt chemotherapeutic agent within last 6 month Use systemic antiviral medication oseltamivir within last 7 day . Intubated mechanically ventilated secondary brain injury alone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Critical Illness</keyword>
	<keyword>Critical Care</keyword>
	<keyword>Valganciclovir</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Aciclovir</keyword>
	<keyword>Valaciclovir</keyword>
	<keyword>Cytomegalovirus</keyword>
</DOC>